dean baker pharmaceuticals

Vote “Outperform” if you believe ADMS will outperform the S&P 500 over the long term. Synaptogenix has conducted the first placebo-controlled, Phase 2 trial of a protein kinase C epsilon (PKCɛ) activator for the treatment of Alzheimer’s, which in preclinical studies induced the growth of new synapses and prevented neuronal death. Identify stocks that meet your criteria using seven unique stock screeners. ABC, where the first letter will represent a Center, and the secondary and tertiary letters will be used by the Centers to direct transactions In the past three months, Adamas Pharmaceuticals insiders have sold more of their company's stock than they have bought. Alzheimer’s disease is the most common form of dementia, accounting for 60%-80% of all cases. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes and Vijay Shreedhar. Also free! Looking for new stock ideas? Dr. Ferrillo has more than 30 years of experience in dental education, and ties to various Dental Support Organizations (DSOs). Join 800,000+ investors in-the-know and get a morning e-briefing on market developments, Zacks' Bull Stock of the Day, plus more. Adamas Pharmaceuticals has received 396 “outperform” votes. Born in Quincy, Massachusetts, he received his B.A. This suggests a possible upside of 157.9% from the stock's current price. Adamas Pharmaceuticals issued an update on its FY 2020 One share of ADMS stock can currently be purchased for approximately $4.75. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its quarterly earnings data on Monday, February, 22nd. Earnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.90) to ($1.35) per share. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.11. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Get daily stock ideas top-performing Wall Street analysts. This is a list of companies in the Chicago metropolitan area.The Chicago metropolitan area, or "Chicagoland", is the metropolitan area associated with the city of Chicago, Illinois, and its suburbs.With an estimated population of 9.4 million people, it is the third largest metropolitan area in the United States. The new team codes will follow an alphabetical format, e.g. Specifically, they have bought $0.00 in company stock and sold $64,744.00 in company stock. The P/E ratio of Adamas Pharmaceuticals is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Notable alumni Academia College chancellors, presidents and vice-presidents. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California. Macroaxis provides wealth optimization analytics to investors of all levels and skills from finance students to professional money managers See what's happening in the market right now with MarketBeat's real-time news feed. Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. (Add your “underperform” vote.). Fundamental company data provided by Zacks Investment Research. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Price to Earnings Ratio vs. the Market. Eine Zeitzone ist ein sich auf der Erde zwischen Süd und Nord erstreckendes, aus mehreren Staaten (und Teilen von größeren Staaten) bestehendes Gebiet, in denen die gleiche, staatlich geregelte Uhrzeit, also die gleiche Zonenzeit, gilt (siehe nebenstehende Abbildung).. Search our affiliated experts by practice. Receive a free world-class investing education from MarketBeat. Earnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.90) to ($1.35) per share. 4 brokers have issued twelve-month price targets for Adamas Pharmaceuticals' shares. Learn about financial terms, types of investments, trading strategies and more. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Learn more. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. Adamas Pharmaceuticals has received 54.70% “outperform” votes from our community. Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV). View our full suite of financial calendars and market data tables, all for free. Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021. © American Consumer News, LLC dba MarketBeat® 2010-2021. Adamas Pharmaceuticals does not currently pay a dividend. View all of ADMS's competitors. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Do Not Sell My Information. Adamas Pharmaceuticals' management team includes the following people: Head of Corp. Communications, Patient Advocacy & Engagement, Head of Corp. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. To see all exchange delays and terms of use please see disclaimer. Want to see which stocks are moving? The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings. Learn everything you need to know about successful options trading with this three-part video course. Administered Oath August 18, 2016. Updated world stock indexes. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. U.S. Customs and Border Protection (CBP) has designated new Centers of Excellence and Expertise (Centers) team codes within the Automated Commercial Environment (ACE) modules. MarketBeat just released five new trading ideas, but Adamas Pharmaceuticals wasn't one of them. Today, you will also receive our 7 Best Stocks for the Next 30 Days. On average, they anticipate Adamas Pharmaceuticals' share price to reach $12.25 in the next year. According to analysts' consensus price target of $12.25, Adamas Pharmaceuticals has a forecasted upside of 157.9% from its current price of $4.75. This includes personalizing content and advertising. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Get short term trading ideas from the MarketBeat Idea Engine. Adamas Pharmaceuticals does not have a long track record of dividend growth. View Adamas Pharmaceuticals' Short Interest. Based on an average daily trading volume, of 528,500 shares, the days-to-cover ratio is currently 1.7 days. View which stocks are hot on social media with MarketBeat's trending stocks report. Get an overview of major world indexes, current values and stock market data. Life Sciences: Selected Experts Complex litigation demands specialized expertise. 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. Adamas Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. Top institutional shareholders include Morgan Stanley (3.88%), Renaissance Technologies LLC (3.15%), Stonepine Capital Management LLC (2.83%), BlackRock Inc. (1.88%), Silverarc Capital Management LLC (1.55%) and Essex Investment Management Co. LLC (0.97%). Devel., Strategy , Portfolio Planning & Alliance Management, Sr. VP of Commercial Operations & Market Access, Start Your Risk-Free Trial Subscription Here, Warren Buffett again encourages investors to bet on America, Biden team readies wider economic package after virus relief, The Latest: U.S. FDA approves J&J single-shot vaccine, Fraud overwhelms pandemic-related unemployment programs, In oil-rich Iraq, a few women buck norms, take rig site jobs, The Latest: At 100, Captain Tom Moore honored at funeral, J&J’s 1-dose shot cleared, giving US 3rd COVID-19 vaccine, Cronos Stock Pulls Back After Earnings, It Might Be Time To Buy Some, Guardion Health Sciences Stock Needs to Give Investors More Than Survival, Wait For a Better Price Before Placing a Bet On Churchill Downs, 3 Small Cap Dividend Stocks with Growth Prospects, It’s Okay to Take the Over on DraftKings Stock, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q4 2020 Results - Earnings Call Transcript, Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering, Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering, Adamas Pharmaceuticals: Q4 Earnings Insights, Adamas Pharmaceuticals, Inc. to Host Earnings Call, Adamas Reports Fourth Quarter and Full Year 2020 Financial Results, A Preview Of Adamas Pharmaceuticals's Earnings, Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021, ADMS Gets FDA Nod, ARQT Soars On Psoriasis Trial Data, DVAX Catches Eye, PRTA On Watch, Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes, Pre-market Movers In Healthcare Sector: ADMS, VXRT, BCRX, CATB…, Biotech Stocks Awaiting FDA Decision In February, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. To learn more, click here. Pre-Market earnings guidance on Wednesday, January, 13th. Their forecasts range from $12.00 to $12.50. He has served as Dean of Southern Illinois University, School of Dental Medicine, and University of Nevada, Las Vegas, School of Dental Medicine.He was also Dean and Interim Provost at University of the Pacific, Arthur A. Dugoni School of Dentistry. View insider buying and selling activity for Adamas Pharmaceuticals or view top insider-selling stocks. Only 19.70% of the stock of Adamas Pharmaceuticals is held by insiders. Learn more. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]. You can opt out at any time. View which stocks have been most impacted by COVID-19. Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter. Currently, 4.0% of the shares of the company are short sold. Adamas Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Adamas Pharmaceuticals has a market capitalization of $145.20 million and generates $54.64 million in revenue each year. As of February 12th, there was short interest totaling 923,500 shares, a decline of 47.8% from the January 28th total of 1,770,000 shares. Compare Top Brokerages Here. 2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. Each of the logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc. We use cookies to understand how you use our site and to improve your experience. The P/E ratio of Adamas Pharmaceuticals is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. There are currently 1 hold rating and 3 buy ratings for the stock. Local anesthetics have been widely used as simple and effective treatment for these disorders, but the duration of their effect is short. Adamas Pharmaceuticals has received a consensus rating of Buy. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. View analysts' price targets for Adamas Pharmaceuticals or view top-rated stocks among Wall Street analysts. 10 S. Riverside Plaza, Suite 1600 | Chicago Illinois 60606. During his tenure at the School, he has served as Senior Associate Dean for University Affairs (including Faculty Chair of the Harvard Innovation Lab), for Research, for Executive Education, for Faculty Development, and for Faculty Recruiting. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Frank M. Gaziano, Associate Justice, was appointed to the Supreme Judicial Court by Governor Charlie Baker. View our earnings forecast for Adamas Pharmaceuticals. 44.23% of the stock of Adamas Pharmaceuticals is held by institutions. Some companies that are related to Adamas Pharmaceuticals include Eagle Pharmaceuticals (EGRX), Evelo Biosciences (EVLO), Inventiva (IVA), Summit Therapeutics (SMMT), XBiotech (XBIT), Geron (GERN), IDEAYA Biosciences (IDYA), Applied Therapeutics (APLT), IVERIC bio (ISEE), Molecular Templates (MTEM), AC Immune (ACIU), Flexion Therapeutics (FLXN), Relmada Therapeutics (RLMD), Bicycle Therapeutics (BCYC) and Urovant Sciences (UROV). MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. All rights reserved. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Adamas Pharmaceuticals saw a decline in short interest in the month of February. The consensus among Wall Street research analysts is that investors should "buy" Adamas Pharmaceuticals stock. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. View institutional ownership trends for Adamas Pharmaceuticals. View analyst ratings for Adamas Pharmaceuticals or view top-rated stocks. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Srikant M. Datar became the eleventh dean of Harvard Business School on 1 January 2021. The official website for Adamas Pharmaceuticals is www.adamaspharma.com. Valeant Pharmaceuticals International tops the ranking of Canadian CEO salaries for a second time this year—and that’s after a $100 million pay cut. ADMS stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Deltec Asset Management LLC, Essex Investment Management Co. LLC, Squarepoint Ops LLC, Engineers Gate Manager LP, Fisher Asset Management LLC, Baker BROS. Advisors LP, and Northern Trust Corp. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, and Vijay Shreedhar. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. Innovative pharmaceutical manufacturing company On Demand Pharmaceuticals (ODP) has selected Rockville in Montgomery County, MD for its new Good Manufacturing Practice (GMP) manufacturing, research, development, and headquarters facility. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. View Adamas Pharmaceuticals' earnings history. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Zacks' free daily newsletter Profit from the Pros provides #1 Rank "Strong Buy" stocks, etfs and more to research for your financial portfolio. Breaking news headlines about Business linking to 1,000s of websites from around the world We identify the most effective experts from our global network of academics, industry specialists, former regulators, and experienced in-house professionals to address the unique objectives of every matter. You may vote once every thirty days. Find the latest business news on Wall Street, jobs and the economy, the housing market, personal finance and money investments and much more on ABC News The company provided earnings per share (EPS) guidance of for the period. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. from Lafayette College in 1986, and earned a J.D., magna cum laude, from Suffolk Law School in 1989.He began his legal career at the Boston law firm of Foley Hoag as a litigation associate. We would like to show you a description here but the site won’t allow us. Export data to Excel for your own analysis. Shares of ADMS can be purchased through any online brokerage account. ), Adamas Pharmaceuticals has received 328 “underperform” votes. (Add your “outperform” vote. ADMS stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Silverarc Capital Management LLC, Stonepine Capital Management LLC, Renaissance Technologies LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., and BlackRock Inc.. View insider buying and selling activity for Adamas Pharmaceuticals or or view top insider-buying stocks. Please log in to your account or sign up in order to add this asset to your watchlist. High institutional ownership can be a signal of strong market trust in this company. Vote “Underperform” if you believe ADMS will underperform the S&P 500 over the long term. Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Adamas Pharmaceuticals employs 136 workers across the globe. The management of persistent postsurgical pain and neuropathic pain remains a challenge. Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS.". The company issued revenue guidance of $74.2-74.2 million, compared to the consensus revenue estimate of $75.15 million. Since then, ADMS stock has increased by 55.7% and is now trading at $4.75. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.